Is acute heart failure a distinctive disorder? An analysis from BIOSTAT‐CHF

Davison, B. A. et al. (2021) Is acute heart failure a distinctive disorder? An analysis from BIOSTAT‐CHF. European Journal of Heart Failure, 23(1), pp. 43-57. (doi: 10.1002/ejhf.2077) (PMID:33340221)

[img] Text
227940.pdf - Accepted Version
Restricted to Repository staff only until 19 December 2021.

2MB

Abstract

Aims: This retrospective analysis sought to identify markers that might distinguish between acute heart failure (HF) and worsening HF in chronic outpatients. Methods and Results: The BIOSTAT‐CHF index cohort included 2516 patients with new or worsening HF symptoms: 1694 enrolled as inpatients (acute HF) and 822 as outpatients (worsening HF in chronic outpatients). A validation cohort included 935 inpatients and 803 outpatients. Multivariable models were developed in the index cohort using clinical characteristics, routine laboratory values, and proteomics data to examine which factors predict adverse outcomes in both conditions and to determine which factors differ between acute HF and worsening HF in chronic outpatients, validated in the validation cohort. Patients with acute HF had substantially higher morbidity and mortality (6 months mortality was 12..3% for acute HF and 4..7% for worsening HF in chronic outpatients). Multivariable models predicting 180‐day mortality and 180‐day HF re‐admission differed substantially between acute HF and worsening HF in chronic outpatients. CA‐125 was the strongest single biomarker to distinguish acute HF from worsening HF in chronic outpatients, but only yielded a C‐index of 0..71. A model including multiple biomarkers and clinical variables achieved a high degree of discrimination with a C‐index of 0..913 in the index cohort and 0..901 in the validation cohort. Conclusion: The study identifies different characteristics and predictors of outcome in acute HF patients as compared to outpatients with chronic HF developing worsening HF. The markers identified may be useful in better diagnosing acute HF and may become targets for treatment development.

Item Type:Articles
Additional Information:BIOSTAT-CHF was funded by the European Commission [FP7-242209-BIOSTAT-CHF; EudraCT 2010-020808-29].
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Cleland, Professor John
Authors: Davison, B. A., Senger, S., Sama, I. E., Koch, G. G., Mebazaa, A., Dickstein, K., Samani, N. J., Metra, M., Anker, S. D., Cleland, J. G., Ng, L. L., Mordi, I. R., Zannad, F., Filippatos, G. S., Hillege, H. L., Ponikowski, P., Veldhuisen, D. J., Lang, C. C., Meer, P., Núñez, J., Bayés‐Genís, A., Edwards, C., Voors, A. A., and Cotter, G.
Subjects:R Medicine > R Medicine (General)
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
Journal Name:European Journal of Heart Failure
Publisher:Wiley
ISSN:1388-9842
ISSN (Online):1879-0844
Published Online:19 December 2020
Copyright Holders:Copyright © 2020 European Society of Cardiology
First Published:First published in European Journal of Heart Failure 23(1): 43-57
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record